Medigene AG
MediGene AG english
Ad-hoc-announcement processed and transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
PROGRESS IN DRUG DEVELOPMENT INCREASED MEDIGENE’S
REVENUES DURING THE FIRST HALF OF 2001 BY 23%
Martinsried / San Diego, August 23, 2001. MediGene (Neuer Markt MDG), the
German-American biotechnology company today announced its six-month report
documenting positive growth.
Revenues (i.e. “other operating income”) climbed by 23 % in the first half of
2001 to 2.846 million Euro in comparison with 2.313 million Euro in the same
period of 2000. This rise in revenues is based on progress in the development of
new drugs generating milestone payments from pharma partners.
The portfolio of new drug candidates undergoing clinical trials was expanded
from five to seven. This improves the company’s probability of success and has
led to a planned increase in the deficit in this period in comparison with the
same period of the previous year. EBIT amounted to -14.404 million Euro at the
time of this report in comparison with -4.167 million Euro for the same period
last year. Loss of the period went from -5.675 million Euro for the first half
of 2000 to -10.932 million Euro for the first six months of 2001.
Cash, cash equivalents and securities in the amount of 100 million Euro (81% of
the total assets) or 9 Euro per share forms the foundation for the scheduled
development and marketing of drugs to treat cardiac and cancer diseases.
Parallel to MediGene’s development activities, the establishment of
the “Marketing/Sales” division is going ahead at full steam. Here MediGene has
the support of Mr. Klaus-Peter Schröder, the former Head of Marketing & Sales
and General Manager of Schering-Plough subsidiaries.
The detailed six-month interim report may be obtained from
http://www.medigene.com/englisch/berichte.php.
This press release contains forward-looking statements that involve risks and
uncertainties. The forward-fooking statements contained herein represent the
judgement of MediGene as of the date of this release. These forward looking
statements are no guarantees for future performance, and the forward-looking
events discussed in this press release may not occur. MediGene disclaims any
intent or obligation to update any of these forward-looking statements.
For further information please contact:
MediGene AG email: investor@mediqene.com
fax: ++49 – 89 – 89 56 32-20
Christine Bohner, Manager Public Relations phone: ++49 – 89 – 89 56 32-16
Michael Nettersheim, Manager Investor Relations phone: ++49 – 89 – 89 56 32-46
end of ad-hoc-announcement (c)DGAP 23.08.2001
——————————————————————————–
WKN: 502090; Index: NEMAX- 50
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
230830 Aug 01
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found